Literature DB >> 31751848

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study.

Kari Röhrl1, Marianne Grønlie Guren2, Guro Lindviksmoen Astrup3, Milada Cvancarova Småstuen4, Tone Rustøen5.   

Abstract

PURPOSE: Multiple symptoms can have a negative impact on quality of life (QoL), but there is little information about the impact of multiple symptoms on QoL of patients with colorectal cancer (CRC) during outpatient chemotherapy. Therefore, the purpose was to assess the physical and mental QoL in CRC patients over six months of chemotherapy, to evaluate the association of QoL with the presence of multiple symptoms, and to determine which demographic and clinical characteristics are associated with physical and mental QoL scores.
METHODS: Outpatients with CRC (N = 120) completed the Medical Outcomes Study Short Form (SF-12) and Memorial Symptom Assessment Scale (MSAS) at eight time points during six months of chemotherapy. Linear mixed models for repeated measures were used to analyse QoL over time; and its association with demographic and clinical characteristics; and with the presence of multiple symptoms (e.g., 'numbness/tingling' and 'problems with sexual interest').
RESULTS: The CRC patients had worse physical and mental QoL scores than the general population at all time points. Impaired physical QoL was significantly associated with psychological symptom burden (p < 0.001) and numbness/tingling (p < 0.027). Impaired mental QoL was associated with physical symptom burden (p < 0.001), with being female (p < 0.009), younger age (p < 0.024), and having problems with sexual interest (p < 0.009).
CONCLUSIONS: Impaired QoL was associated with symptoms in CRC outpatients. This information about the symptoms and characteristics associated with worse QoL during chemotherapy may help clinicians identify and inform at-risk patients.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; MSAS; Quality of life; Symptoms

Year:  2019        PMID: 31751848     DOI: 10.1016/j.ejon.2019.101679

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  5 in total

1.  Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients.

Authors:  Na Li; Jiajia Lu; Duanxiang Xia; Xuetong Jiang; Xiaomeng Wen; Xia Qin; Ying Chen; Teng Wang
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Implementing Symptom Management Follow-up Using an Electronic Patient-Reported Outcome Platform in Outpatients With Advanced Cancer: Longitudinal Single-Center Prospective Study.

Authors:  Lili Tang; Yi He; Ying Pang; Zhongge Su; Jinjiang Li; Yening Zhang; Xu Wang; Xinkun Han; Yan Wang; Zimeng Li; Shuangzhi He; Lili Song; Yuhe Zhou; Bingmei Wang; Xiumin Li
Journal:  JMIR Form Res       Date:  2022-05-10

3.  Distress management in cancer patients: Guideline adaption based on CAN-IMPLEMENT.

Authors:  Liang Fu; Yang Yang; Yan Hu; Zhenqi Lu; Xiaoju Zhang; Mingzhu Huang; Yuanyuan Li; Fuzhong Zhu; Yang Wang; Zhe Huang
Journal:  Int J Nurs Sci       Date:  2021-12-16

Review 4.  Understanding the psychosocial impact of colorectal cancer on young-onset patients: A scoping review.

Authors:  Athena Ming-Gui Khoo; Jerrald Lau; Xin-Sheng Loh; Celeste Wen-Ting Ng; Konstadina Griva; Ker-Kan Tan
Journal:  Cancer Med       Date:  2022-02-11       Impact factor: 4.452

5.  Prospective Evaluation of the Quality of Life of Patients after Surgical Treatment of Rectal Cancer: A 12-Month Cohort Observation.

Authors:  Magdalena Tarkowska; Iwona Głowacka-Mrotek; Bartosz Skonieczny; Michał Jankowski; Tomasz Nowikiewicz; Marcin Jarzemski; Wojciech Zegarski; Piotr Jarzemski
Journal:  J Clin Med       Date:  2022-10-07       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.